RE: Low as it gets easy 100% profit20 Nov 2019 14:53
People have forgotten just a quick reminder
stronger-than-expected performance from its opioid-addiction treatment Suboxone.
It now expects full-year 2019 revenue to be in the range of $750m to $790m, up from previous guidance of between $670m and $720. Meanwhile, net income is expected to come in between $160m and $190m, up from a previous range of $80m to $130m.